Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.66 |
| ▸ | CXCR1 | P25024 | 13/20 | 0.57 |
| ▸ | CCR7 | P32248 | 2/20 | 0.56 |
| ▸ | CCR6 | P51684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14308591 | 0.84 | CXCR2 (0.51) | CXCR2CXCR1 | |
| SCHEMBL14319674 | 0.84 | CXCR2 (0.64) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL18870053 | 0.83 | CXCR2 (0.72) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL248850 | 0.83 | CXCR2 (0.72) | CXCR2CXCR1 | |
| SCHEMBL14453379 | 0.82 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL19351994 | 0.82 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL949803 | 0.82 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL2019927 | 0.82 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL30515684 | 0.82 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL247336 | 0.82 | CXCR2 (0.74) | CXCR2CXCR1CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-2178826-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME (US) | 2017-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | CXCR1, CXCR2, FPR2 | CXCR2 2/4885CXCR1 1/4885CCR7 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.